Johnson & Johnson (JNJ)
← Portfolio overview
$
255.56
Last Close
+13.3%
since purchase
$
25,556
Position Value
$3,001
unrealized gain
+14.3
%
Total Return (Est.)
$235
estimated dividends
$
277.91
Analyst Target
+8.7%
from last close
Holdings
Ticker
Return
CVX
+16.8
%
JNJ
+13.3
NVDA
+9.0
Jun
2026
Jul
Aug
Sep
Oct
220
240
260
$280
close
Bought at
Price Since Purchase
Daily close, with the purchase price for reference
4
May'26
11
18
25
1
Jun
8
15
22
29
6
Jul
13
20
27
3
Aug
10
17
24
31
7
Sep
14
21
28
5
Oct
12
−10.0%
−5.0%
0.0%
5.0%
10.0%
Weekly Returns
Compounded from daily closes, week starting Monday
0
5
10
Strong buy
Buy
Hold
Sell
Strong sell
0
Analyst Ratings
Number of analysts at each rating
Fundamentals
Metric
Current
Market cap
$653.6B
P/E (trailing)
31.5
P/E (forward)
21
PEG ratio
2.82
EPS (TTM)
$8.62
Profit margin
21.5%
Return on equity
25.7%
Revenue growth (YoY)
+6.6%
Dividend yield
1.94%
Beta
0.23
52-week range
$177.06 to $281.07
Latest quarter
30 Jun 2026
Company Profile
Company
Johnson & Johnson
Sector
Healthcare
Industry
Drug manufacturers - general
Exchange
NYSE (USD)
Address
ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, UNITED STATES, 08933
Website
https://www.jnj.com
Fiscal year end
December
Business
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones
Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only
two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Data as of 13:13 UTC on 17 Oct 2026
made with
dbt Charts